United States FDA status: Not approved
Whilst mild, temporary sleep changes may occur as your body adjusts to Wegovy, certain situations warrant prompt medical consultation : Contact your GP or prescribing clinician if you experience: Persistent insomnia lasting more than 23 weeks despite implementing sleep hygiene measures Severe daytime fatigue that impairs your ability to function safely (particularly if driving or operating machinery) Sleep disturbances accompanied by mood changes, including low mood, anxiety, or irritability Symptoms suggesting sleep apnoea (loud snoring, witnessed breathing pauses, morning headaches, excessive daytime sleepiness) Neck swelling, difficulty swallowing, or persistent hoarseness (thyroid symptoms requiring assessment) Right upper abdominal pain, especially after eating (possible gallbladder issues, which are associated with GLP-1 receptor agonists) [11] [18] Seek urgent medical attention (call 999 or go to A&E) if: You experience severe, persistent abdominal pain, especially if radiating to the back and accompanied by vomiting (possible pancreatitis) You develop severe chest pain You have signs of jaundice (yellowing of the skin/eyes) with fever and abdominal pain (possible acute gallbladder disease) Your healthcare provider can assess whether sleep disturbances are related to Wegovy, another underlying condition, or the weight loss process itself
However, in 2006 it became clear that GIP(3-42) does not function as a physiological antagonist in vivo as its maximal circulating levels are insufficient to elicit antagonistic effects (48)
Retatrutide depletes electrolytes through multiple mechanisms
